Abstract
BackgroundGamma-glutamyl transpeptidase (GGT) which plays an important role in tumor initiation, invasion, drug resistance is strongly associated with poor prognosis in patients with cancers. This study was designed to estimate whether pretreatment serum GGT could predict the clinical outcome of nasopharyngeal carcinoma (NPC) patients.ResultsAn optimal cutoff value was identified as 23 U/L for GGT. Univariate analysis and multivariate analysis demonstrated that elevated GGT was correlated with shorter local recurrence-free survival (LRFS) (HR, 4.163; 95% CI, 1.690-10.251; p=0.023), progression-free survival (PFS) (HR, 3.119; 95% CI, 1.955-4.976; p=0.031) and overall survival (OS) (HR, 2.811; 95% CI, 1.614-4.896; p=0.007).Materials and MethodsWe retrospectively analyzed data from 374 patients with NPC. Kaplan–Meier method was used to calculate and compare the prognosis. The Cox proportional hazards model was applied to carry out univariate and multivariate analyses.ConclusionPretreatment GGT can be a novel and independent prognostic biomarker for patients with NPC.
Highlights
Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers in Southeast Asia, especially in Southern China
Univariate analysis and multivariate analysis demonstrated that elevated Gamma-glutamyl transpeptidase (GGT) was correlated with shorter local recurrence-free survival (LRFS) (HR, 4.163; 95% CI, 1.690-10.251; p=0.023), progression-free survival (PFS) (HR, 3.119; 95% CI, 1.955-4.976; p=0.031) and overall survival (OS) (HR, 2.811; 95% CI, 1.614-4.896; p=0.007)
Plenty of evidences had shown that some molecular makers, such as lactate dehydrogenase (LDH) [5], neutrophil-lymphocyte ratio, platelet-lymphocyte ratio [6], Epstein-Barr virus [7] and c-reactive protein [8] could successfully stratify patients regarding to their prognosis
Summary
Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers in Southeast Asia, especially in Southern China. Locoregional recurrence and distant metastasis after treatment still remain the main failure patterns affecting the survival rate of patients with advanced NPC [3]. Searching for biomarkers associated with the prognosis of NPC patients are urgently needed [4]. Patients even with the same TNM stages could have dramatically different survival results [7]. These inexpensive, objective and detected markers are of great value to complement the TNM staging system. Gamma-glutamyl transpeptidase (GGT) which plays an important role in tumor initiation, invasion, drug resistance is strongly associated with poor prognosis in patients with cancers. This study was designed to estimate whether pretreatment serum GGT could predict the clinical outcome of nasopharyngeal carcinoma (NPC) patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
